BRD9876 |
Catalog No.GC48901 |
BRD9876 est l'inhibiteur de \BRD9876 is the "rigor" inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs.en_fr_2022q1.mdBRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket.en_fr_2022q1.mdBRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells.en_fr_2022q1.mdBRD9876 has the potential for multiple myeloma (MM) research.en_fr_2022q1.md
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 32703-82-5
Sample solution is provided at 25 µL, 10mM.
BRD9876 is an inhibitor of the kinesin spindle protein Eg5.1 It arrests Eg5-mediated microtubule gliding, as well as inhibits Eg5 ATPase activity in the presence of microtubules, in cell-free assays. BRD9876 is cytotoxic to MM.1S stroma-independent multiple myeloma cells (IC50 = 2.2 µM). It induces cell cycle arrest at the G2/M phase in MM.1S cells when used at a concentration of 10 µM.
1.Chattopadhyay, S., Stewart, A.L., Mukherjee, S., et al.Niche-based screening in multiple myeloma identifies a kinesin-5 inhibitor with improved selectivity over hematopoietic progenitorsCell Rep.10(5)755-770(2015)
Average Rating: 5
(Based on Reviews and 33 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *